60 results
Page 2 of 3
8-K
EX-99.1
432gc89vm3u32k
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.2
f97xtt4279cnjc5z
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.2
2kbxb9jyqbvju6vfpwxl
10 Nov 21
Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones
7:03am
8-K
EX-99.2
utbmed bl7fd
19 May 21
Regulation FD Disclosure
5:00pm
S-3ASR
EX-1.2
65g41n
2 Apr 21
Automatic shelf registration
4:59pm
8-K
EX-1.1
a7ovr6my1l75lw4uz3k
9 Dec 20
Entry into a Material Definitive Agreement
4:38pm
424B5
8qrsw87 nv
9 Dec 20
Prospectus supplement for primary offering
4:02pm
424B5
kd3h1hsz8mqzl
7 Dec 20
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.2
pnm7g0hk
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am